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Courten3, Kirsty Wilson4, Robert Scragg5, Magdalena Plebanski4 & Barbora de Courten1
In-vitro studies suggest that vitamin D reduces inflammation by inhibiting nuclear factor kappa-B 
(NFκB) activity. Yet, no trials have examined the effects of vitamin D supplementation on NFκB activity 
in-vivo in humans. We conducted a double-blind randomized trial (RCT) examining effects of vitamin 
D supplementation on inflammatory markers and NFκB activity in peripheral blood mononuclear 
cells (PBMCs). Sixty-five overweight/obese, vitamin D-deficient (25-hydroxyvitamin D [25(OH)D] ≤ 50 
nmol/L) adults were randomized to a single 100,000 IU bolus followed by 4,000 IU daily cholecalciferol 
or matching placebo for 16 weeks. We measured BMI, % body fat, serum 25(OH)D, high-sensitivity 
C-reactive protein (hsCRP), tumour necrosis factor (TNF), monocyte chemoattractant protein-1 (MCP-
1), interferon-gamma (IFN-γ), several interleukins, and NFκB activity in PBMCs. Fifty-four participants 
completed the study. Serum 25(OH)D concentrations increased with vitamin D supplementation 
compared to placebo (p < 0.001). Vitamin D and placebo groups did not differ in any inflammatory 
markers or NFκB activity (all p > 0.05). Results remained non-significant after adjustment for age, sex, 
and % body fat, and after further adjustment for sun exposure, physical activity, and dietary vitamin D 
intake. Although in-vitro studies report anti-inflammatory effects of vitamin D, our RCT data show no 
effect of vitamin D supplementation on inflammatory markers or NFκB activity in-vivo in humans.
Chronic low-grade inflammation is common in obesity and plays an important role in the etiology of many 
chronic diseases including type 2 diabetes and cardiovascular disease1. While reducing obesity is effective in 
reducing inflammation and delaying disease onset and progression, weight-loss strategies on a population scale 
are difficult to achieve and maintain in the long-term1. Identification of additional easily modifiable risk factors is 
therefore needed to mitigate risk factors associated with chronic diseases, including inflammation.
Increasing evidence suggests that vitamin D may have a role in inflammation and immunoregula-
tion2. Yet, vitamin D deficiency remains prevalent worldwide3. Most experts define vitamin D deficiency as 
25-hydroxyvitamin D (25(OH)D) concentrations ≤ 50 nmol/L; however optimal concentrations required for 
extra-skeletal health are debated3. Nevertheless, it is of concern that 20–60% and 10–40% of the UK and US pop-
ulations, respectively, have vitamin D levels < 50 nmol/L4. An adequate vitamin D status is achieved primarily 
via cutaneous synthesis upon exposure to ultraviolet (UV) B radiation, and can also be derived from diet and 
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supplements5. However, the rising prevalence of obesity, sedentary indoor lifestyles, and current sun exposure 
restrictions to prevent skin cancer have made it difficult to obtain adequate vitamin D through sun exposure, and 
few foods are naturally high in vitamin D or vitamin D fortified6.
A role for vitamin D in influencing inflammatory and immune responses is supported by the presence of the 
nuclear vitamin D receptor (VDR) in most immune cells including monocytes, macrophages, and activated T 
and B lymphocytes [10]. In vitro studies report that active vitamin D (1,25-dihydroxyvitamin D3 [1,25(OH)2D3]) 
inhibits pro-inflammatory cytokine expression, promotes anti-inflammatory cytokine production, and regulates 
immune cell activity7–9. These effects are believed to occur partly via inhibition of the nuclear factor kappa-B 
(NFκB) pathway10–14, a transcription factor with a critical role in inflammatory and immune responses, as well as 
in the pathophysiology of several chronic diseases such as cancer, asthma, and diabetes15,16. In vivo administration 
of 1,25(OH) 2D3 in mice has been shown to modulate chemokine and cytokine expression and to prevent the 
development of inflammatory arthritis, type 1 diabetes, and autoimmune encephalomyelitis17. Animal models 
also show that treatment with 1,25(OH)2D3 reduces NFκB signaling by increasing VDR expression18,19.
Human studies are limited. To the best of our knowledge, no previous observational studies or randomized 
trials have examined the effect of vitamin D on NFκB activity in vivo in humans. For inflammatory markers, 
some20–23, but not all24,25, cross-sectional studies have reported inverse associations between 25(OH)D concen-
trations and C-reactive protein (CRP), tumor necrosis factor (TNF), and interleukin-6 (IL-6) in healthy21–23 or 
overweight/obese populations20. However, few good-quality randomized controlled trials (RCTs) have examined 
the effects of vitamin D supplementation on inflammatory markers. A recent systematic review of RCTs in over-
weight and obese individuals highlighted important limitations in existing trials including low supplementation 
doses, variability in participants’ vitamin D status, lack of assessment of lifestyle factors (diet, exercise, sun expo-
sure), and the use of co-interventions including calcium and/or weight reduction programs in most trials26. These 
limitations have made it difficult to interpret findings.
We aimed to address these limitations by examining the effects of vitamin D supplementation on inflam-
matory markers and NFκB activity in overweight or obese but otherwise healthy individuals, with vitamin 
D-deficiency (25(OH)D ≤ 50 nmol/L), who receive a sufficient dose (≥4000 IU daily) of supplementation, in a 
clinical trial without co-interventions and with rigorous methods to minimize confounding by lifestyle factors. 
We hypothesized that vitamin D supplementation would decrease pro-inflammatory markers and NFκB activity 
and increase anti-inflammatory markers, compared with placebo.
Methods
Study Design and Participants. This study was part of a parallel-group, double-blind, randomized, place-
bo-controlled trial designed to assess the effects of vitamin D supplementation on insulin sensitivity and secretion, 
and a detailed trial protocol is published27. Briefly, 65 overweight/obese but otherwise healthy adults were recruited 
over a two-year period from the local community in Melbourne, Australia, via posters, flyers, email newsletters 
and online social media and community websites. Participants were screened and those with serum 25(OH)
D concentrations ≤ 50 nmol/L on screening were recruited if they met the following inclusion criteria: aged 
18–60 years, generally healthy on medical screening, overweight or obese (body mass index (BMI) ≥ 25 kg/m2; 
weight < 159 kg due to facility restrictions), with a stable weight (<5 kg change in the preceding year) and no 
intention to lose weight or change their diet or physical activity for the trial duration. Exclusion criteria included: 
smoking or high alcohol use (>4 and >2 standard drinks/week for men and women, respectively); use of med-
ication, vitamins, or supplements; hypercalcemia or allergies; diabetes (previously diagnosed or based on oral 
glucose tolerance test [OGTT]) or any major diseases including active cancer in the preceding 5 years; or presence 
of acute inflammation (based on medical history or physical or laboratory examination). Women who were preg-
nant, lactating, or experiencing menopause were excluded.
Ethics. All participants provided written informed consent prior to commencing the trial. The trial was con-
ducted according to the principles of the Declaration of Helsinki28 and received ethical approval from the Monash 
University Human Research Ethics Committee and Monash Health (Protocol ID: CF13/3874-2013001988). The 
trial was registered on clinicaltrials.gov (ID: NCT02112721) on April 10th, 2014.
Intervention and Randomization. Participants were randomized to either the vitamin D group receiving 
an initial bolus dose of 100,000 IU (in 2 capsules) followed by 4,000 IU (in 4 capsules) of cholecalciferol daily, or 
the placebo group receiving an equivalent number of identical placebo capsules, which were continued daily for 
a period of 16 weeks. The bolus dose selected is well below levels associated with toxicity or adverse effects29. All 
participants were instructed to consume the four capsules daily, and maintain their usual diet and exercise habits.
Randomization was performed as described previously27. Briefly, randomization was performed by an 
independent researcher not involved in the trial using a computerized random sequence generation program. 
Participants were randomized in blocks of four by sex and time of study entry (seasons) to ensure balance 
between sexes in each test group and to control for the effect of seasonal change. All capsules were identical and 
tasteless to maintain blinding, and all participants, investigators, and outcome assessors remained blinded until 
data analysis was complete. Compliance was assessed by the empty pill containers returned by participants at the 
final follow up visit and by post-intervention 25(OH)D concentrations.
Data Collection and Analyses. Detailed descriptions of data collection and outcome measures are 
reported in our published protocol27. Outcome measures were obtained at baseline prior to the initial bolus of 
vitamin D and repeated after 16 weeks of supplementation. Participants who were eligible on phone screening 
attended a medical screening which included medical history, physical examination (including anthropometry, 
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and pregnancy tests for women), measurement of serum 25(OH)D concentrations to document vitamin D status, 
and an OGTT to exclude diabetes according to World Health Organization guidelines30.
Anthropometric and Lifestyle Assessments. Body composition was measured by dual X-ray absorptiometry 
(DEXA) (Monash Health Radiology, Melbourne). Body mass index (BMI) was calculated from weight (kg)/
square of height (m), and waist and hip circumferences were used to establish the waist-to-hip ratio (WHR) 
as an additional index for body fat distribution (waist (mm)/hip (mm) = WHR). Participants completed vali-
dated questionnaires assessing self-reported sun exposure habits, physical activity (International Physical Activity 
Questionnaire)31, and diet (3-day food record; Foodworks 8.0 Professional, Xyris Software, Australia).
Blood Sample Analyses. Fasting venous blood samples were drawn at baseline, and then after the 16-week inter-
vention using standard phlebotomy techniques into serum separation vacutainers for measurement of serum 
inflammatory markers and 25(OH)D concentrations, respectively. All blood samples were analyzed under 
blinded conditions using standard quality control systems (all results within ± 2 SD). Serum 25(OH)D and hsCRP 
were measured by an accredited and quality-assured laboratory (Monash Health Pathology, Melbourne). Serum 
25(OH)D was measured using direct competitive chemiluminescent immunoassays (CLIA) (DiaSorin Inc., MN, 
USA) with inter- and intra-assay coefficients of variation (CVs) of <10% and <4%, respectively. Plasma high 
sensitivity CRP (hsCRP) was measured by highly sensitive near-infrared particle immunoassay rate methodol-
ogy on a Synchron LX system analyzer (Beckman Coulter Inc., Sydney, Australia) according to manufacturer’s 
instructions. Inter- and intra-assay CVs for hsCRP were <3% and <5%, respectively. Inflammatory markers were 
measured using a bead-based multi-analyte assay (LEGENDplex™ Human Inflammation panel, Cat. 740118; 
Biolegend, San Diego, CA). This panel was used to simultaneously quantify 13 pro- and anti- inflammatory 
cytokines/chemokines including TNF, monocyte chemoattractant protein-1 (MCP-1), interferon alpha (IFN-α) 
and gamma (IFN- γ), and IL-1β, IL-6, IL-8, IL-10, IL-12, IL-17A, IL-18, IL-23, and IL-33. Serum samples were 
diluted 2-fold based on preliminary testing and the kit-specified protocol was performed on 96-well v-bottom 
plates as follows. Sonicated pre-mixed beads, serum samples, cytokine standards, and detection antibodies were 
added to each well and then plates were incubated (in the dark) on a plate shaker at 600 rpm for 2 hours at room 
temperature (RT). Following incubation, streptavidin–phycoerythrin (SA-PE) solution was added to each well 
and further incubated on a plate shaker for 30 min at RT. The conjugated beads were then centrifuged (1000 g, 
5 minutes, RT) and pelleted, and resuspended in wash buffer before being transferred to mini FACS tubes for data 
acquisition. Data acquisition was performed using the BD™ LSR II flow cytometer and FACS DIVA software 
set up as per manufacturer’s instructions (Becton Dickinson, San Diego, CA). Data were analyzed using the 
LEGENDplex™ Data Analysis Software (BioLegend, San Diego, CA) with standard curves generated from 0 to 
50,000 pg/ml, and samples adjusted for the dilution factors. Inter- and intra-assay CVs for all analytes were <8% 
and <9%, respectively. Of the 13 cytokines, two were undetectable (IFN-γ and IL17A) in most of the samples and 
were therefore excluded from the analysis.
Measurement of NFκB activity. Peripheral blood mononuclear cells (PBMCs) were isolated by centrifuging 
fasting whole blood samples collected in BD Vacutainer® CPT™ cell preparation tubes with sodium citrate. The 
harvested PBMC pellet was resuspended in fetal bovine serum (FBS) with 10% dimethylsulphoxide (DMSO) and 
stored at −80 °C. Immediately prior to analysis, PBMC samples were thawed and washed in excess phosphate 
buffered saline (PBS) and centrifuged (400 g, 5 minutes, 4 °C) to remove residual FBS and DMSO. The superna-
tant was discarded and the pellets resuspended in 100 μL of triple detergent buffer. These were then sonicated 
for 1 minute and then centrifuged (400 g, 3 minutes, 4 °C). Resulting supernatant was used in the NFκB assay. 
Protein concentration of all protein isolates was determined using the Pierce Bicinchoninic Acid protein assay 
(Pierce, Rochford, IL), performed according to manufacturer’s instructions. The TransAM NFκB DNA-binding 
activity assay (Active Motif, Carlsbad, CA) was used to detect and quantify NFκB transcription factor activation, 
specifically of the p65 subunit. Nuclear extracts obtained from PBMC samples (30 μg protein per well) were ana-
lyzed for their binding capacity to an NFκB consensus sequence in labelled DNA in a 96 well plate format. The 
assays were performed according to manufacturer’s instructions and absorbance was measured on a Victor3V 
Multilabel plate reader (Perkin Elmer, Wellesley, MA). Results are expressed as pg p65 activity per μg protein (pg/
μg protein).
Statistical Analyses. The sample size calculation has been reported elsewhere27, and was based on the 
main study where insulin sensitivity was the primary outcome. Analyses were performed on a per-protocol basis 
using Stata V.12.1 (StatCorp LP, USA). Shapiro-Wilk tests and visual inspection of histograms and scatterplots 
were used to assess normality with the assistance of an experienced biostatistician. Baseline characteristics are 
presented as mean ± SD and frequencies (%), or median (interquartile range [IQR]) for skewed variables. Due 
to the skewed distributions of the inflammatory markers and NFκB activity, all results were analyzed using 
non-parametric tests. Spearman correlations and Mann-Whitney U-tests were used to examine associations at 
baseline between 25(OH)D concentrations and continuous and categorical variables, respectively. Within-group 
differences were assessed using Wilcoxon signed-rank tests. Differences between treatments groups were assessed 
using Mann-Whitney U-tests and chi-squared tests for continuous and categorical variables, respectively. Efficacy 
of the intervention on the outcomes (between-group differences) were analyzed using changes in outcome var-
iables and quantile multiple regression (to examine difference in medians). In quantile multiple regression, we 
adjusted for those variables which were significantly associated with the outcome measure based on Spearman 
correlations, as well as other clinically relevant variables including baseline values, age, sex, and % body fat, 
and factors which may affect vitamin D status including season, sun exposure, and dietary vitamin D intake. 
Pre-specified subgroups including those with baseline 25(OH)D ≤ 30 nmol/L were assessed as well as obese 
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(BMI ≥ 30 kg/m2) subgroups. Further exploratory analyses were conducted in subgroups of participants with 
high baseline concentrations (≥median values) of selected inflammatory markers. All tests were two-sided and 
Bonferroni correction was used to adjust for multiple testing (p = 0.05/total number of tests (n = 13) = 0.004). 
Statistical significance was therefore set at p < 0.004.
Data Availability. The datasets generated and analysed during the current study are available from the cor-
responding author on reasonable request.
Results
Sample and baseline characteristics. The participant flowchart is presented in Fig. 1. Of 1,072 partic-
ipants screened for eligibility, 132 attended medical screening and 65 were successfully randomized between 
September 2014 and July 2016 (33 and 32 in the vitamin D and placebo groups, respectively) (Fig. 1). By the 
end of the study, nine participants had dropped out and two were withdrawn (one due to protocol violation and 
one due to an adverse event of thrombophlebitis after an intravenous glucose tolerance test). The remaining 54 
participants (vitamin D group = 28 and placebo group = 26) completed the study and were analyzed in a blinded 
per-protocol fashion. Baseline demographic, anthropometric, and biochemical characteristics of both groups are 
presented in Table 1. Baseline characteristics did not differ between drop outs and non-drop outs (all p > 0.05) 
(data not shown).
Thirty-five male and 19 female participants aged 30 (25–36) years (median [IQR]) with a BMI of 30.1 (27.7–
33.2) kg/m2, and % body fat of 39.6 ± 8.7% (mean ± SD) completed the study. Mean baseline serum 25(OH)D 
concentration was 32.7 ± 11.4 nmol/L (range = 9–50 nmol/L), with 43% of participants (n = 23) having a 25(OH)
D concentration ≤ 30 nmol/L. Demographic, anthropometric and biochemical measures did not differ between 
the treatment groups at baseline, nor did physical activity, dietary intake of vitamin D (Table 1), or diet compo-
sition comprising of total energy, protein, fiber, fat, and carbohydrate intake (data not shown). Baseline 25(OH)
D concentrations were not associated with age or anthropometric measures or with baseline values or change 
scores for any of the outcome measures (all p > 0.1; data not shown). CRP levels at baseline were positively asso-
ciated with total % body fat (r = 0.40, p = 0.002) and fat mass (r = 0.30, p = 0.03) and both CRP and IL-33 were 
Figure 1. Participant Flowchart: Numbers of participants who were recruited, randomized, dropped out, and 
analyzed during the trial. aMajority of interested participants did not meet criteria due to taking medication/
supplements; not being overweight/obese; or not being interested after receiving a detailed description of 
study procedures. Abbreviations: 25(OH)D, 25-hydroxyvitamin D; OGTT, oral glucose tolerance test; PCOS, 
polycystic ovary syndrome; SSRIs, selective serotonin reuptake inhibitors.
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negatively associated with fat-free mass (r = −0.33, p = 0.01 and r = −0.27, p = 0.04, respectively). Patient char-
acteristics including age and anthropometric variables were not associated with other inflammatory markers or 
NFκB activity at baseline (all p > 0.05; data not shown). NFκB activity at baseline was inversely associated with 
baseline levels of TNF, IL10, IL-1β, IL-8, IL-12, IL-23, and IL-33 (all p < 0.05; data not shown).
Changes in serum 25(OH)D concentrations. As previously reported32, mean serum 25(OH)D concentration 
after the 16-week intervention was 63.2 ± 32.1 (range = 9–147 nmol/L). Serum 25(OH)D concentrations increased 
significantly in the vitamin D group, from 31.4 ± 12.6 at baseline to 88.4 ± 21.0 nmol/L at 16 weeks (p < 0.001), with 
no change in the placebo group for the same time-period (34.2 ± 10.0 and 36.1 ± 15.3 nmol/L, respectively; p = 0.5) 
(Table 2). All but one participant in the vitamin D group achieved a 25(OH)D concentration ≥ 60 nmol/L, with 82% 
(n = 23/28) and 64% (n = 18/28) having 25(OH)D concentrations >70 and >75 nmol/L at follow-up, respectively.
Effect of vitamin D supplementation on serum pro- and anti- inflammatory markers and NFκB activ-
ity in PBMCs. There were no differences between vitamin D and placebo groups in change in hsCRP (−0.1 ± 1.4 
versus −0.4 ± 2.3 mg/L, p = 0.9), TNF (−8.0 ± 109.4 versus −2.9 ± 103.9 pg/ml, p = 0.9), MCP-1 (−234.8 ± 1071.9 
versus −58.8 ± 819.4 pg/ml, p = 0.6) or IFN-α (11.1 ± 85.8 versus −1.3 ± 22.7 pg/ml, p = 0.9). Similarly, no differences 
between vitamin D and placebo groups were found for any of the interleukins (all p > 0.1; Table 2). Changes in pro-/
anti-inflammatory marker ratios including hsCRP/IL-10, TNF/IL-10 and IL-6/IL-10 ratios also did not differ between 
groups (data not shown). Change in NFκB activity in PBMCs did not differ between vitamin D and placebo groups 
(−17.8 ± 31.9 versus −13.2 ± 32.4 pg/μg protein, p = 0.7; Table 2); however change in NFκB activity within the vitamin 
D group (between baseline and follow up) trended toward significance (p = 0.05; Table 2).
Results for all inflammatory markers and NFκB activity remained non-significant in multiple regression anal-
yses adjusted for baseline values, age, sex, ethnicity, and season of blood collection (all p > 0.1; Table 3, Model 
1). Replacing ethnicity and season of blood collection in the multivariable model with factors which may affect 
vitamin D status including dietary vitamin D intake, sun exposure, and physical activity did not alter the results 
(all p > 0.1; Table 3, Model 2). Results remained non-significant in a third model adjusting for baseline values 
and factors which are clinically relevant to both vitamin D status and inflammation including change in % body 
fat, dietary vitamin D intake, diet composition (as fat/carbohydrate ratio), physical activity, and sun exposure (all 
p > 0.1; Table 3, Model 3). Addition of protein and/or fiber intake to the models as well as replacing % body fat 
with fat mass only or with BMI and WHR did not change the results (data not shown).
Sub-group Analyses. Results of the subgroup analyses are presented in Table 4. Pre-specified subgroup 
analysis was conducted in participants with 25(OH)D concentrations ≤30 nmol/L (n = 23; 15 males/8 females; 
age = 32.0 ± 7.6 years). In this subgroup, baseline 25(OH)D concentration was 21.7 ± 5.7 nmol/L (range = 9–29 
nmol/L), with a mean BMI of 30.5 ± 4.2 kg/m2 and % body fat of 40.3 ± 8.7%. Baseline demographic, anthro-
pometric, and biochemical characteristics did not differ between groups (data not shown). Serum 25(OH)D 
concentrations increased in the vitamin D group compared to placebo (59.9 ± 20.2 versus 6.9 ± 18.4 nmol/L, 
p < 0.001). There were no significant differences between vitamin D and placebo groups in any of the pro- or 
anti-inflammatory markers measured (all p > 0.1; Table 4). NFκB activity also did not differ between vitamin D 
and placebo groups in this subgroup (p = 0.3; Table 4).
Characteristics Vitamin D group (n = 28) Placebo group (n = 26) p
Male, n (%) 17 (60.7) 18 (69.2) 0.5
Age (years) 30.5 (25–35) 29.5 (25–41) 0.9
Ethnicitya, n
 Caucasian 9 5
0.2
 South and Central Asian 8 9
 South-East and North-East Asian 4 9
 Otherb 5 2
Sun exposure (index score)c 4.2 (1.6–6.3) 5.1 (2.0–6.9) 0.5
Physical activity (IPAQ-METS score)c 1751 (920–3510) 2912 (1485–5544) 0.2
Dietary vitamin D intake (IU)c 91.1 (54.6–130.9) 73.1 (61.0–110.8) 0.3
Season of blood collection, n (%)
          Winter 5 (17.8) 8 (30.7)
0.3
          Spring 11 (39.3) 4 (15.4)
          Summer 8 (28.6) 10 (38.5)
          Autumn 4 (14.3) 4 (15.4)
Table 1. Participant demographics and baseline characteristics. Data are expressed as frequency (n, %) or 
median (interquartile range), unless otherwise specified. p = Mann-Whitney U-tests and chi-squared tests for 
baseline differences between treatment groups; aEthnicity was determined by self-report (n = 51/54 reported 
ethnicity); brefers to African, Middle-Eastern, South-American, and Polynesian ethnicities; ccalculated 
from self-reported questionnaires and food records as previously reported27; Abbreviations: IPAQ-METS, 
international physical activity questionnaire- multiples of the resting metabolic rate.
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Subgroup analysis was also conducted to explore the effects of vitamin D supplementation in obese participants 
(BMI ≥ 30 kg/m2) (n = 28; 13 males/15 females; age = 33.7 ± 9.0 years). Mean baseline 25(OH)D concentration 
in this subgroup was 34.6 ± 11.1 nmol/L (range = 9–50 nmol/L), with a BMI of 34.1 ± 3.8 kg/m2 and % body fat 
of 44.2 ± 8.4%. There were no differences between groups in demographic, anthropometric or biochemical char-
acteristics at baseline. Changes in pro- and anti-inflammatory markers and NFκB activity did not differ between 
vitamin D and placebo groups in this subgroup of obese participants (Table 4). Further exploratory analyses were 
conducted to examine the effects of vitamin D supplementation in subgroups of participants with high baseline 
concentrations (≥median values) of selected inflammatory markers and NFκB activity. Changes in inflammatory 
markers and NFκB activity did not differ between vitamin D and placebo groups in subgroups of participants with 
high CRP (≥2.0 mg/L), IL-6 (≥21.0 pg/ml), TNF (≥28.0 pg/ml) or NFκB activity (≥37.0 pg/μg protein) (data not 
shown). Finally, we compared those in the vitamin D group who reached a 25(OH)D concentration >70 nmol/L 
(n = 23) or >75 nmol/L (n = 18) at follow up with the placebo group (n = 23 with 25(OH)D < 50 nmol/L at follow 
up) and found no differences in any of the parameters measured (all p > 0.05; data not shown).
Discussion
This randomized placebo-controlled trial examined the effect of oral cholecalciferol (100,000 IU bolus followed 
by 4,000 IU daily) supplementation for 16 weeks on pro- and anti-inflammatory markers and NFκB activity 
in overweight or obese but otherwise healthy individuals with vitamin D deficiency (25(OH)D ≤ 50 nmol/L). 
Despite a significant increase in 25(OH)D concentration in the vitamin D group, we found no differences between 
vitamin D and placebo groups in any of the pro- or anti- inflammatory markers measured, including hsCRP, TNF, 
MCP-1, IFN-α, and IL-1β, -6, -8, -10, -12, -18, -23, and -33, as well as no difference in NFκB activity in PBMCs. 
Adjustment for potential confounders did not alter the results and similar results were found in subgroup anal-
yses of individuals with 25(OH)D ≤ 30 nmol/L, obese individuals (BMI > 30 kg/m2), or individuals with higher 
inflammatory marker or NFκB concentrations at baseline (concentrations ≥ median for hsCRP, TNF, IL-6, and 
NFκB activity).
Previous RCTs in overweight and obese but otherwise healthy adults have reported similar findings. A recent 
meta-analysis of 13 RCTs26 including 1,995 overweight and obese participants reported that vitamin D supplementa-
tion had no effect on plasma CRP, TNF, or IL-6 concentrations. With the exception of three trials33–35, all the included 
Outcome Variable
Vitamin D Group (n = 28) Placebo Group (n = 26)
p3 p4Baseline Follow Up p1 Change Baseline Follow Up p2 Change
25(OH)D (nmol/L) 31.4 ± 12.6 88.4 ± 21.0 <0.001 57.0 ± 21.3 34.2 ± 10.0 36.1 ± 15.3 0.5 1.9 ± 15.1 0.4 <0.001
BMI (kg/m2) 30.2 (28.4, 34.5) 30.4 (28.7, 34.5) 0.9 0.003 ± 0.9 29.8 (27.6, 32.6) 29.2 (27.5, 32.6) 0.5 −0.1 ± 1.2 0.4 0.7
WHR 0.94 ± 0.08 0.93 ± 0.07 0.06 −0.01 ± 0.04 0.93 ± 0.04 0.94 ± 0.04 0.9 0.001 ± 0.02 0.5 0.2
% body fat 40.3 ± 8.2 39.9 ± 8.1 0.1 −0.4 ± 1.6 38.8 ± 9.4 38.5 ± 9.2 0.3 −0.3 ± 1.7 0.4 0.9
Fat mass (kg) 36.4 ± 9.8 36.0 ± 9.4 0.3 −0.5 ± 2.1 33.7 ± 10.2 33.4 ± 10.6 0.4 −0.3 ± 2.4 0.3 0.9
Fat free mass (kg) 53.9 ± 12.9 54.2 ± 12.7 0.2 0.3 ± 1.4 53.1 ± 12.2 53.0 ± 11.9 0.3 −0.9 ± 1.5 0.9 0.1
hsCRP (mg/L) 2.6 (1.0, 5.8) 2.0 (1.2, 5.2) 0.9 −0.1 ± 1.4 1.1 (0.9, 3.1) 1.3 (0.6, 2.7) 0.8 −0.4 ± 2.3 0.1 0.9
TNF (pg/ml) 29.6 (14.6, 55.0) 24.3 (11.1, 45.6) 0.3 −8.0 ± 109.4 27.6 (16.9, 72.9) 21.5 (12.4, 47.4) 0.2 −2.9 ± 103.9 0.8 0.9
MCP-1 (pg/ml) 625 (398.4, 951.4) 554.1 (429.6, 925.6) 0.6 −234.8 ± 1071.9 713.0 (483.2, 1087.3) 562.5 (402.5, 851.5) 0.3 −58.8 ± 819.4 0.6 0.6
IFN-α (pg/ml 12.8 (9.8, 27.9) 13.1 (6.5, 23.7) 0.6 11.1 ± 85.8 13.6 (8.4, 28.8) 10.8 (7.4, 22.5) 0.4 −1.3 ± 22.7 0.8 0.9
IL-1β (pg/ml) 15.2 (10.3, 30.1) 14.3 (4.4, 23.2) 0.5 −3.1 ± 39.0 20.1 (9.2, 39.0) 13.8 (6.7, 19.4) 0.3 −4.8 ± 38.1 0.7 0.6
IL-6 (pg/ml) 20.1 (10.0, 30.9) 16.4 (6.0, 35.4) 0.2 −7.7 ± 75.1 21.7 (11.8, 44.4) 14.5 (7.2, 35.2) 0.4 −4.7 ± 65.4 0.6 0.9
IL-8 (pg/ml) 12.7 (7.8, 18.6) 12.2 (7.6, 23.2) 0.8 −2.4 ± 21.9 14.6 (10.2, 24.1) 11.6 (8.8, 17.8) 0.3 −1.2 ± 20.5 0.3 0.7
IL-10 (pg/ml) 8.1 (6.5, 12.9) 7.2 (5.2, 10.4) 0.1 −2.6 ± 20.2 8.7 (6.2, 17.0) 7.4 (5.9, 10.1) 0.3 −0.9 ± 13.3 0.9 0.9
IL-12 (pg/ml) 7.4 (5.4, 9.9) 6.3 (4.6, 8.4) 0.2 −0.8 ± 11.5 6.9 (5.4, 13.0) 5.9 (5.1, 7.6) 0.2 −0.9 ± 10.2 0.9 0.9
IL-18 (pg/ml) 174.7 (101.9, 284.5) 129.1 (87.7, 210.4) 0.2 −100.0 ± 381.9 196.1 (112.1, 265.2) 117.4 (81.2, 211.9) 0.2 −4.7 ± 291.9 0.6 0.9
IL-23 (pg/ml) 25.5 (19.6, 41.3) 17.6 (12.9, 39.3) 0.2 −7.4 ± 126.4 28.6 (16.2, 73.0) 22.4 (9.0, 38.3) 0.2 −10.8 ± 60.5 0.8 0.8
IL-33 (pg/ml) 34.2 (10.4, 118.6) 37.0 (5.4, 79.2) 0.7 −16.2 ± 236.3 48.6 (24.0, 211.0) 23.4 (5.4, 64.4) 0.2 −14.5 ± 228.1 0.4 0.5
NFκB activity in PBMCs 
(pg/μg protein) 33.6 (26.6, 63.6) 28.6 (23.2, 35.1) 0.05 −17.8 ± 31.9 38.2 (23.1, 67.1) 27.7 (23.0, 34.8) 0.2 −13.2 ± 32.4 0.8 0.7
Table 2. Comparison of outcomes before and after 16 weeks of supplementation in both groups. Data are 
expressed as mean ± standard deviation, or median (interquartile range) for non-normally distributed 
variables, unless otherwise specified. Analyses adjusted for multiple testing using Bonferroni correction, 
such that P < 0.004 was considered statistically significant. p1 = Wilcoxon sign rank tests for differences 
between baseline and follow up within vitamin D group; p2 = Wilcoxon sign rank tests for differences 
between baseline and follow up within placebo group; p3 = Mann-Whitney U-tests for differences at baseline 
between vitamin D and placebo groups; p4 = Mann-Whitney U-tests for differences in change scores between 
vitamin D and placebo groups. Abbreviations: 25(OH)D, 25-hydroxyvitamin D; BMI, body mass index; 
WHR, waist-to-hip ratio; hsCRP, high-sensitivity C-reactive protein; TNF, tumor necrosis factor; MCP-1, 
monocyte chemoattractant protein-1; IL, interleukin; NFκB, nuclear factor kappa-B; PBMC, peripheral blood 
mononuclear cells.
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RCTs reported no effect of vitamin D supplementation on several pro- and anti-inflammatory markers includ-
ing but not limited to hsCRP, TNF, MCP-1, and several interleukins (IL-2, -4, -5, -6, -8, -10, -12, -13, and -17)26. 
Of the three studies which found a beneficial effect, one had co-supplemented vitamin D with calcium33, and 
another combined vitamin D with a weight reduction program35. This makes results difficult to interpret since 
both calcium and weight loss have been shown to influence levels of circulating inflammatory markers36,37. 
The third study reporting that vitamin D supplementation improved inflammatory markers was limited to 
Dependent Variable (Change)
Model 1 Model 2 Model 3
β SE p β SE p β SE p
hsCRP (mg/L) 0.24 0.54 0.7 −0.15 0.45 0.7 −0.29 0.58 0.6
TNF (pg/ml) 3.41 10.91 0.8 1.42 12.63 0.9 0.15 11.44 0.9
MCP-1 (pg/ml) −53.64 169.50 0.8 4.26 177.93 0.9 −5.45 241.60 0.9
IFN-α (pg/ml) 0.27 7.54 0.9 0.24 6.19 0.9 1.00 6.21 0.9
IL-1β (pg/ml) 4.27 5.54 0.4 1.57 6.36 0.8 0.61 6.83 0.9
IL-6 (pg/ml) −2.37 8.19 0.8 0.94 9.98 0.9 0.50 9.08 0.9
IL-8 (pg/ml) 0.18 4.08 0.9 2.08 4.79 0.7 −0.37 4.71 0.9
IL-10 (pg/ml) −0.58 1.69 0.7 −0.47 2.41 0.8 0.81 2.96 0.8
IL-12 (pg/ml) 0.58 1.24 0.6 −0.23 1.24 0.9 −0.75 1.48 0.6
IL-18 (pg/ml) −1.48 45.48 0.9 −2.62 48.03 0.9 −43.09 45.50 0.4
IL-23 (pg/ml) −1.43 9.23 0.9 −7.64 12.92 0.6 −4.51 17.60 0.8
IL-33 (pg/ml) 2.31 28.88 0.9 15.10 39.12 0.7 13.70 41.69 0.7
NFκB activity (pg/μg protein) −0.25 4.05 0.9 2.23 3.15 0.5 4.48 3.70 0.2
Table 3. Multivariable regression analysis for differences in outcomes between the vitamin D group and 
placebo group (reference group) after adjustment for covariates. Data was analyzed using quantile (median) 
regression for differences in median change scores between groups after adjusting for covariates (placebo 
group as reference group). Results presented as unstandardized beta coefficients (β), standard error (SE), and 
corresponding p-values. All analyses were adjusted for multiple testing using Bonferroni correction, such that 
p < 0.004 was considered statistically significant. Model 1: adjusted for baseline values, age, sex, ethnicity, and 
season of blood collection; Model 2: adjusted for baseline values, age, sex, change in dietary vitamin D intake, 
physical activity (international physical activity questionnaire-multiples of the resting metabolic rate), and sun 
exposure index; Model 3: adjusted for baseline values, % body fat, dietary vitamin D intake, diet composition 
(fat/carbohydrate ratio), physical activity (international physical activity questionnaire-multiples of the resting 
metabolic rate), and sun exposure index. Abbreviations: hsCRP, high-sensitivity C-reactive protein; TNF, tumor 
necrosis factor; MCP-1, monocyte chemoattractant protein-1; IL, interleukin.
Outcome Variable  
(Change scores)
25(OH)D < 30 nmo/L Subgroup (n = 23) BMI > 30 kg/m2 Subgroup (n = 28)
Vitamin D Group 
(n = 14)
Placebo Group 
(n = 9) p
Vitamin D Group 
(n = 13)
Placebo Group 
(n = 15) p
25(OH)D (nmol/L) 59.9 ± 20.2 6.9 ± 18.4 <0.001 48.5 ± 19.7 −2.1 ± 12.1 <0.001
hsCRP (mg/L) −0.1 ± 1.4 −1.5 ± 3.3 0.5 0.3 ± 1.3 0.3 ± 1.6 0.8
TNF (pg/ml) 3.5 ± 146.9 −27.1 ± 49.6 0.3 −24.4 ± 82.5 −18.6 ± 60.1 0.9
MCP-1 (pg/ml) −291.9 ± 1404.8 −86.4 ± 712.2 0.6 −320.8 ± 1319.3 −235.8 ± 529.9 0.3
IFN-α (pg/ml) 28.7 ± 119.7 −5.4 ± 17.4 0.4 −5.9 ± 22.0 −3.9 ± 8.4 0.7
IL-1β (pg/ml) 6.4 ± 50.3 −10.4 ± 22.7 0.1 −10.5 ± 24.9 −11.4 ± 21.2 0.7
IL-6 (pg/ml) 7.1 ± 91.2 −21.8 ± 42.4 0.5 −23.8 ± 60.4 −14.2 ± 42.1 0.8
IL-8 (pg/ml) 0.9 ± 30.3 −4.8 ± 12.7 0.2 −6.0 ± 22.3 −5.4 ± 10.4 0.5
IL-10 (pg/ml) −1.6 ± 28.4 −4.6 ± 8.3 0.5 −4.0 ± 9.5 −3.2 ± 8.9 0.7
IL-12 (pg/ml) 1.0 ± 15.8 −3.2 ± 5.7 0.3 −3.0 ± 7.4 −2.2 ± 5.5 0.9
IL-18 (pg/ml) −135.9 ± 530.5 −99.5 ± 203.6 0.7 −59.8 ± 220.8 −57.6 ± 169.0 0.4
IL-23 (pg/ml) 25.8 ± 140.0 −23.5 ± 44.6 0.3 −37.6 ± 109.0 −21.5 ± 38.9 0.7
IL-33 (pg/ml) 17.1 ± 315.9 −49.7 ± 97.4 0.1 −55.5 ± 172.3 −47.3 ± 114.4 0.6
NFκB activity (pg/μg 
protein) −11.7 ± 37.9 5.8 ± 19.3 0.4 −26.7 ± 25.7 −17.2 ± 37.8 0.3
Table 4. Subgroup analyses of participants with 25-hydroxyvitamin D concentrations ≤ 30 nmol/L and 
participants with a body mass index ≥ 30 kg/m2. Data are expressed as mean ± standard deviation for change 
scores. All analyses performed using Mann-Whitney U-tests for differences between groups, and adjusted 
for multiple testing using Bonferroni correction, such that p < 0.004 was considered statistically significant. 
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; hsCRP, high-sensitivity C-reactive protein; TNF, tumor 
necrosis factor; MCP-1, monocyte chemoattractant protein-1; IL, interleukin.
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South American women34. This may explain their discrepant finding since polymorphisms in the VDR and 
metabolizing enzymes which affect the absorption and genetic functions of vitamin D are known to differ by 
ethnicity34,38.
Overall, existing RCTs in overweight and obese populations are limited by several important factors. First, 
most RCTs did not take into account participant smoking status, season, sun exposure, or dietary vitamin D 
intake – factors which may have influenced their results39,40. Second, 80% of existing RCTs were not in vitamin 
D-deficient individuals and this group has been proposed to benefit most from vitamin D supplementation41. 
Although we found no effect in our subgroup analysis of participants with 25(OH)D concentrations ≤ 30 nmol/L, 
this may be due to the small sample size. Importantly, the two largest RCTs33,42 (n = 928 and n = 332) in over-
weight and obese adults were in participants without vitamin D deficiency (baseline 25(OH)D range = 56–136 
nmol/L), and both trials reported increased CRP concentrations after one year of supplementation with 20,000–
40,000 IU of cholecalciferol weekly33,42. This suggests that high doses of vitamin D in non-deficient participants 
may be detrimental43, and highlights the need for similar large-scale studies that are restricted to individuals 
with vitamin D deficiency. Third, it has been suggested that at least 4,000 IU daily is required to raise 25(OH)
D concentrations to optimal levels within 2–3 months44,45. Yet, more than half of the RCTs supplemented low 
doses (700–2000 IU daily) which may have been insufficient to adequately raise 25(OH)D concentrations. Here, 
we address these knowledge gaps by showing that vitamin D supplementation, provided in a sufficient dose to 
vitamin D-deficient individuals, did not improve circulating pro- or anti-inflammatory marker concentrations, 
which persisted after adjusting for multiple confounders. Based on our findings and those from most other stud-
ies, current evidence does not support the use of vitamin D supplementation for improving inflammation in 
overweight or obese, but otherwise healthy individuals.
However, vitamin D supplementation may be beneficial in other population groups including those with existing 
chronic or inflammatory diseases. RCTs and systematic reviews of RCTs have shown that vitamin D supplementa-
tion improved inflammatory marker concentrations in patients with chronic heart failure46, systemic lupus erythe-
matosus47, inflammatory bowel disease48, and chronic obstructive pulmonary disease49. Moreover, although RCTs 
in prediabetes have shown no effect of vitamin D supplementation on inflammatory markers50–52, a meta- analysis 
by our group in patients with type 2 diabetes found that vitamin D-supplemented groups had lower levels of CRP 
and TNF compared to placebo (Mousa, unpublished data). It has been suggested that the effects of vitamin D on 
the immune system are more prominent when the immune system is impaired or stimulated53. Differences between 
studies may therefore be due to the presence of acute or chronic inflammation in participants with established 
diseases compared to their healthy counterparts. This is supported by a meta-analysis of mixed population groups 
(healthy and with existing diseases; n = 924)54, which found that vitamin D supplementation had a significantly 
greater effect on inflammation in patients with higher CRP levels (>5 mg/L) at baseline, compared to normal ranges. 
Subgroup analysis of participants with CRP levels >5 mg/L was not possible in our study due to the small number of 
participants with elevated CRP (n = 11). Moreover, although we found no differences between vitamin D and pla-
cebo groups in our subgroup analyses of participants with baseline concentrations > the median for CRP, TNF, IL-6, 
and NFκB activity, our sample size may have been too small to observe effects in these subgroups (n = 27). Future 
studies in healthy individuals should consider including large samples of vitamin D-deficient participants with a 
wide range of inflammatory marker concentrations at baseline in order to confirm whether vitamin D supplemen-
tation improves pro- and anti- inflammatory profiles in this population group.
We found no effect of vitamin D supplementation on NFκB activity in PBMCs. To the best of our knowledge, this 
is the first study to investigate the effects of vitamin D supplementation on NFκB activity in vivo in humans. Only 
experimental human studies and animal models have investigated this relationship to date, most of which reported 
that vitamin D inhibits NFκB activity in several human cell types including macrophages, fibroblasts, keratino-
cytes, pancreatic islet cells, and adipocytes10–14. These in vitro studies have consistently shown that treatment with 
active vitamin D (1,25(OH)2D3) increases mRNA and protein levels of IκBα (an inhibitor of nuclear translocation 
of NFκB), which in turn decreases NFκB activity and DNA-binding capacity, and reduces nuclear translocation of 
the NFκB p65 subunit10–14. However, some studies showed that 1,25(OH)2D3 can both stimulate and inhibit NFκB 
in different types of myeloid leukemic cells55,56. This suggests that vitamin D may influence NFκB activity in a cell- 
and tissue- specific manner. Similarly, in vivo animal models have shown that the VDR directly regulates the NFκB 
pathway57, and that treatment with active 1,25(OH)2D3 or analogs (eg: paricalcitol) increases VDR expression, with 
concomitant reductions in the NFκB signaling cascade18,19. Our finding of no effect of vitamin D supplementation 
on NFκB activity in PBMCs seems to conflict with the widely reported inhibitory effect of vitamin D in experimen-
tal and animal models. However, experimental studies have explored the active form of vitamin D, 1,25(OH)2D3, 
and have utilized different stimuli including bacteria, viruses, or agents like lipopolysaccharide (LPS) that activate 
transcription factors including NFκB58. Because our study measured 25(OH)D rather than 1,25(OH)2D3, and NFκB 
activity was measured in unstimulated PBMCs, these factors may partly explain the discrepancy between our find-
ings and those from experimental studies. Moreover, vitamin D and NFκB may function differently in the natural 
biological environment in humans (ie: in vivo) compared to what is observed in animals or under experimental con-
ditions. For instance, a study by Wamberg et al.14 in obese individuals found that 1,25(OH)2D3 treatment inhibited 
cytokine expression in vitro; however no effect was observed after in vivo treatment with 1,25(OH)2D3 in the same 
population. This suggests that in some circumstances, extrapolation of in vitro findings to the in vivo context may 
not be appropriate. Here, we show for the first time that vitamin D supplementation has no effect on in vivo NFκB 
activity in vitamin-deficient and overweight or obese but otherwise healthy individuals. Further studies are needed 
to corroborate our finding and to examine whether these effects may differ in other cell types or among other popu-
lations including those with existing inflammatory or chronic diseases.
Our study has several strengths, particularly the use of rigorous methodology and a double-blind randomized 
controlled design. This was the first study investigating the effects of vitamin D supplementation on NFκB activity 
in vivo in humans. We studied overweight or obese participants with vitamin D deficiency who were more likely 
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to be at increased risk of inflammation and who have been proposed to benefit most from vitamin D supplemen-
tation. Compliance to study medication was high, with 82% of participants in the intervention group achieving 
25(OH)D concentrations >70 nmol/L at follow-up. Our study sample comprised of a well-characterized cohort 
of healthy individuals where there was no confounding by disease status or medication use. We were able to adjust 
for important confounders including season, sun exposure, and dietary vitamin D intake- factors which have 
seldom been considered in previous studies.
Some limitations should be noted. Pro- and anti- inflammatory markers and NFκB activity were secondary 
outcomes of the main trial where the sample size calculation was based on changes in insulin sensitivity27. Our 
sample size was therefore not powered to detect differences in these outcomes or to draw valid conclusions from 
subgroup analyses. Moreover, most participants had hsCRP levels within a normal range (<5 mg/L) and narrow 
ranges for most of the other inflammatory markers. This may have contributed to our null findings since any 
changes in inflammatory markers would have been minimal, thereby requiring a much larger sample size in order 
to detect small effect sizes. Additionally, although 82% of participants in the vitamin D group reached a serum 
25(OH)D level >70 nmol/L at follow up, it has been suggested that 25(OH)D concentrations as high as 80–100 
nmol/L may be required for optimal immune function59, which may explain our lack of findings. Because our 
sample comprised of healthy young individuals, our results may not be generalizable to other populations includ-
ing those with existing diseases. We measured NFκB activity in PBMCs, thus our results may not apply to other 
cell or tissue types. Potential contributions by genetic polymorphisms in the VDR or metabolizing enzymes were 
not explored in this study. Although in vitro data suggest that the biologically active vitamin D (1,25(OH)2D3) is 
involved in immunoregulation, we did not measure this form of vitamin D because circulating levels are tightly 
regulated60. Due to resource constraints, we were not able to measure 25(OH)D using the gold-standard liquid 
chromatography-mass spectrometry method, and instead used Diasorin assays which capture both 25(OH)D2 
and 25(OH)D3 concentrations.
In summary, the present study addresses current knowledge gaps by providing high-doses of vitamin D sup-
plementation to vitamin D-deficient individuals, without co-interventions, and with adjustment for important 
confounders – all of which are factors that have not been adequately addressed in previous trials. We found no 
beneficial effect of vitamin D supplementation on circulating pro- and anti-inflammatory markers or NFκB activ-
ity in overweight or obese but otherwise healthy individuals. Our results suggest that vitamin D may function 
differently in the human in vivo context compared to the inhibitory effects reported in in vitro and animal models. 
However, further trials in healthy individuals are needed to corroborate our findings, with the inclusion of: (1) 
large sample sizes with sufficient power to detect small changes; (2) participants with vitamin D-deficiency and a 
wider range of baseline inflammatory marker concentrations; and (3) assessment of whether vitamin D may affect 
in vivo NFκB activity in other cell and tissue types.
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